Journal Article Rituximab-combination chemotherapy achieves a 10th cycle of remission for Burkitt's lymphoma.

Umeda, Katsutsugu  ,  Fujino, Hisanori  ,  Saida, Satoshi  ,  Kato, Itaru  ,  Hiramatsu, Hidefumi  ,  Yamada, Tomomi  ,  Hori, Toshinori  ,  Adachi, Souichi  ,  Heike, Toshio  ,  Watanabe, Ken-ichiro

57 ( 2 )  , pp.e30 - e33 , 2015-04-13 , wiley
A 14-year-old girl with multiple intra-abdominal tumors was diagnosed with stage III Burkitt's lymphoma. She achieved complete remission after multi-drug chemotherapy, but she relapsed after six courses. Autologous peripheral blood stem cells (PBSC) or allogeneic PBSC harvested from an HLA-identical sibling were insufficient, and her family did not agree to bone marrow collection from the sibling. Although the patient relapsed nine times (the relapses involved intra-abdominal organs or bone) during the following 4 years 7 months, treatment with rituximab monotherapy or in combination with ifosphamide, carboplastin, and etoposide, or local irradiation (33.8-40.0 Gy) to treat the bone metastases, proved effective, resulting in complete or partial remission. At the time of writing, the patient was in a 10th cycle of remission lasting 1 year 6 months and had not required transplantation. Thus, a chemotherapy regimen including rituximab might be effective for Burkitt's lymphoma in patients experiencing multiple relapse.

Number of accesses :  

Other information